Volume 96 Issue 11 | p. 9 | News of The Week
Issue Date: March 12, 2018 | Web Date: March 9, 2018

Interest in targeted protein degraders continues in new partnership between Celgene and Vividion

Vividion is using fragment-based screening to develop new drugs, including targeted protein degraders, for ‘undruggable’ proteins
By Ryan Cross
Department: Business
Keywords: Drug discovery, protein degraders, targeted protein degradation, Celgene, Vividion

In another sign of growing pharmaceutical industry interest in targeted protein degradation, Celgene will pay Vividion Therapeutics $101 million in a four-year pact to develop small-molecule drugs for cancer, inflammation, and neurodegenerative diseases.

Vividion was founded in 2014 and raised its first $50 million last year. The start-up’s technology, now being used to develop protein degraders, is based on the work of three Scripps Research Institute . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society